Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gilead: Defending the class

Gilead Sciences Inc.'s announcement late Friday that it will discontinue U.S. development of adefovir dipivoxil to treat HIV comes as no surprise. But the company maintains that the problems that led the FDA's Antiviral Drugs Advisory Committee to vote against approval last month don't apply to related compounds in the company's pipeline.

In November, the FDA panel said that GILD (Foster City, Calif.) had failed to demonstrate the safety

Read the full 689 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE